Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Qi Xinke (iruplinalkib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Qilu Pharma

Drug class:

ALK inhibitor, ROS1 inhibitor

Related drugs:

‹

›

ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	iruplinalkib Sensitive: A1 - Approval iruplinalkib Sensitive : A1	iruplinalkib Sensitive: A1 - Approval iruplinalkib Sensitive : A1
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	iruplinalkib Sensitive: C3 – Early Trials iruplinalkib Sensitive : C3	iruplinalkib Sensitive: C3 – Early Trials iruplinalkib Sensitive : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	iruplinalkib Sensitive: C3 – Early Trials iruplinalkib Sensitive : C3	iruplinalkib Sensitive: C3 – Early Trials iruplinalkib Sensitive : C3
SLC8A1-PKDCC-ALK fusion + ALK overexpression	Lung Adenocarcinoma	SLC8A1-PKDCC-ALK fusion + ALK overexpression	Lung Adenocarcinoma	iruplinalkib Sensitive: C4 – Case Studies iruplinalkib Sensitive : C4	iruplinalkib Sensitive: C4 – Case Studies iruplinalkib Sensitive : C4
SPECC1L‑ALK fusion	Non Small Cell Lung Cancer	SPECC1L‑ALK fusion	Non Small Cell Lung Cancer	iruplinalkib Sensitive: C4 – Case Studies iruplinalkib Sensitive : C4	iruplinalkib Sensitive: C4 – Case Studies iruplinalkib Sensitive : C4
EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	panitumumab + iruplinalkib Sensitive: D – Preclinical panitumumab + iruplinalkib Sensitive : D	panitumumab + iruplinalkib Sensitive: D – Preclinical panitumumab + iruplinalkib Sensitive : D
EGFR C797S + EGFR T790M + EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR C797S + EGFR T790M + EGFR exon 19 deletion	Non Small Cell Lung Cancer	panitumumab + iruplinalkib Sensitive: D – Preclinical panitumumab + iruplinalkib Sensitive : D	panitumumab + iruplinalkib Sensitive: D – Preclinical panitumumab + iruplinalkib Sensitive : D
EGFR C797S + EGFR T790M + EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR C797S + EGFR T790M + EGFR exon 19 deletion	Non Small Cell Lung Cancer	iruplinalkib + QL1203 Sensitive: D – Preclinical iruplinalkib + QL1203 Sensitive : D	iruplinalkib + QL1203 Sensitive: D – Preclinical iruplinalkib + QL1203 Sensitive : D
EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	iruplinalkib + QL1203 Sensitive: D – Preclinical iruplinalkib + QL1203 Sensitive : D	iruplinalkib + QL1203 Sensitive: D – Preclinical iruplinalkib + QL1203 Sensitive : D
EML4-ALK L1196M	Non Small Cell Lung Cancer	EML4-ALK L1196M	Non Small Cell Lung Cancer	iruplinalkib Sensitive: D – Preclinical iruplinalkib Sensitive : D	iruplinalkib Sensitive: D – Preclinical iruplinalkib Sensitive : D
EML4-ALK C1156Y	Non Small Cell Lung Cancer	EML4-ALK C1156Y	Non Small Cell Lung Cancer	iruplinalkib Sensitive: D – Preclinical iruplinalkib Sensitive : D	iruplinalkib Sensitive: D – Preclinical iruplinalkib Sensitive : D